Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26054
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDe, Brian-
dc.contributor.authorNg, Sweet Ping-
dc.contributor.authorLiu, Amy Y-
dc.contributor.authorAvila, Santiago-
dc.contributor.authorTao, Randa-
dc.contributor.authorHolliday, Emma B-
dc.contributor.authorBrownlee, Zachary-
dc.contributor.authorKaseb, Ahmed-
dc.contributor.authorLee, Sunyoung-
dc.contributor.authorRaghav, Kanwal-
dc.contributor.authorVauthey, Jean-Nicolas-
dc.contributor.authorMinsky, Bruce D-
dc.contributor.authorHerman, Joseph M-
dc.contributor.authorDas, Prajnan-
dc.contributor.authorSmith, Grace L-
dc.contributor.authorTaniguchi, Cullen M-
dc.contributor.authorKrishnan, Sunil-
dc.contributor.authorCrane, Christopher H-
dc.contributor.authorGrassberger, Clemens-
dc.contributor.authorHong, Theodore S-
dc.contributor.authorLin, Steven H-
dc.contributor.authorKoong, Albert C-
dc.contributor.authorMohan, Radhe-
dc.contributor.authorKoay, Eugene J-
dc.date2021-
dc.date.accessioned2021-03-15T05:42:17Z-
dc.date.available2021-03-15T05:42:17Z-
dc.date.issued2021-03-03-
dc.identifier.citationJournal of Hepatocellular Carcinoma 2021; 8: 57-69en
dc.identifier.issn2253-5969-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26054-
dc.description.abstractThe immune system plays a crucial role in cancer surveillance. Previous studies have shown that lymphopenia associated with radiotherapy (RT) portends a poor prognosis. We sought to differentiate the effects of proton and photon RT on changes in absolute lymphocyte count (ALC) for patients with hepatocellular carcinoma (HCC). Patients with HCC treated with definitive RT from 2006 to 2016 were studied. Serial ALCs were graded according to CTCAE v4.0. Overall survival (OS), disease-free survival, and distant metastasis-free survival were analyzed using the Kaplan-Meier method. Univariable and multivariable Cox-proportional hazards analyses were used to identify predictors of OS. A cohort analysis matched for treatment volume was performed to investigate differences in ALC dynamics between photon and proton therapy. Of 143 patients identified, the median age was 66 (range, 19-90) years. The treatment modality was photon in 103 (72%) and proton in 40 (28%). Median follow-up was 17 months (95% confidence interval, 13-25 months). The median time to ALC nadir after initiation of RT was 17 days with a median relative decrease of 67%. Those who received proton RT had a higher median ALC nadir (0.41 vs 0.32 k/µL, p=0.002) and longer median OS (33 vs 13 months, p=0.002) than those who received photon RT. Matched cohort analyses revealed a larger low-dose liver volume in the photon group, which correlated with lower ALC. On multivariable Cox analysis, Grade 3 or higher lymphopenia prior to or after RT, portal venous tumor thrombus, larger planning target volumes, Child-Pugh (CP) Class B, and increased CP score after RT were associated with a higher risk of death, whereas the use of proton therapy was associated with lower risk. Grade 3 or higher lymphopenia may be associated with poorer outcomes in patients receiving RT for HCC. Protons may mitigate lymphopenia compared with photons, potentially due to reduced dose exposure of sites of lymphopoiesis.en
dc.language.isoeng-
dc.subjectcirculating lymphocytesen
dc.subjectliver doseen
dc.subjectlymphocyte counten
dc.subjectoverall survivalen
dc.subjectsplenic doseen
dc.titleRadiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Hepatocellular Carcinomaen
dc.identifier.affiliationDepartment of Radiation Oncology, Tufts Medical Center, Boston, MA, USAen
dc.identifier.affiliationDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USAen
dc.identifier.affiliationDepartment of Radiation Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, USAen
dc.identifier.affiliationDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAen
dc.identifier.affiliationDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAen
dc.identifier.affiliationDepartment of Radiation Oncology, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USAen
dc.identifier.affiliationDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAen
dc.identifier.affiliationRadiation Oncologyen
dc.identifier.affiliationDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USAen
dc.identifier.doi10.2147/JHC.S282062en
dc.type.contentTexten
dc.identifier.orcid0000-0003-3468-3359en
dc.identifier.orcid0000-0003-3633-4304en
dc.identifier.orcid0000-0001-7675-3461en
dc.identifier.pubmedid33688489-
Appears in Collections:Journal articles
Files in This Item:
3 files
File Description SizeFormat 
26054.pdf2.96 MBAdobe PDF
Download Adobe
Thumbnail
View/Open
Show simple item record

Page view(s)

12
checked on Sep 22, 2021

Download(s)

8
checked on Sep 22, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.